RemeGen Co., Ltd. (REGMF)

2,0900 0,0000 (0,00%) Börsenschluss: 10:30AM EDT

RemeGen Co., Ltd.

58 Middle Beijing Road
Yantai Development Zone Yantai Area of Shandong Pilot Free Trade
Yantai
China
86 53 56357 3672
https://www.remegen.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 3.615

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Jianmin Fang	Co-Founder, CEO,Member of Scientific Advisory Board & Executive Director	1,14M	N/A	1962
Dr. Ruyi He M.D.	Chief Medical Officer, Head of Clinical Research, Member of Scientific Adv. Board & Executive Dir.	1,05M	N/A	1962
Mr. Jian Lin	Executive Director	122,26k	N/A	1956
Mr. Shaojing Tong	CFO & Joint Company Secretary	N/A	N/A	1972
Mr. Kaisheng Huang	Chief Operating Officer	N/A	N/A	N/A
Dr. Marie Zhu	Chief Technical Officer	N/A	N/A	N/A
Dr. Zhulun Wang	Chief Scientific Officer	N/A	N/A	N/A
Mr. Daniel R. Ross	Chief Business Officer	N/A	N/A	N/A
Dr. Xiaoming Yang Ph.D.	Chief Manufacturing Officer	N/A	N/A	1964
Ms. Pak Yu Tam A.C.I.S., A.C.S.	Joint Company Secretary	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC218 and RC228 to treat ophthalmopathy. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.

Corporate Governance

RemeGen Co., Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.